2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2489

Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy
Abstract Number: 2490

Impact of Obesity Activity Indices and Therapeutic Dosage in Patients with Rheumatoid Arthritis in Dominican Republic
Abstract Number: 2491

Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Abstract Number: 2492

Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Abstract Number: 2493

Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Abstract Number: 2494

The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
Abstract Number: 2495

The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Abstract Number: 2496

DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Abstract Number: 2497

Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
Abstract Number: 2498

Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Abstract Number: 2499

Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Abstract Number: 2500

Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
Abstract Number: 2501

Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Abstract Number: 2502

Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
Abstract Number: 2503

Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].